Cargando…
Longer interval between neoadjuvant chemoradiotherapy and surgery is associated with improved pathological response, but does not accurately estimate survival in patients with resectable esophageal cancer
Neoadjuvant chemoradiotherapy (nCRT) has been shown to reduce tumor burden and achieve tumor regression in patients with esophageal cancer (ESC). However, the most beneficial time interval between the administration of nCRT and surgery remains unclear. Therefore, the aim of the present study was to...
Autores principales: | Liu, Jiaqi, Zeng, Xiaoxiao, Zhou, Xiaojuan, Xu, Yong, Ding, Zhenyu, Hu, Yang, Yuan, Yong, Chen, Longqi, Wang, Jin, Lu, You, Liu, Yongmei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018328/ https://www.ncbi.nlm.nih.gov/pubmed/36936022 http://dx.doi.org/10.3892/ol.2023.13741 |
Ejemplares similares
-
Predictors of pathological complete response to neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma
por: Huang, Ren-Wen, et al.
Publicado: (2014) -
A clinical trial of neoadjuvant concurrent chemoradiotherapy followed by resection for esophageal carcinoma
por: Anvari, Kazem, et al.
Publicado: (2015) -
The Key Clinical Questions of Neoadjuvant Chemoradiotherapy for Resectable Esophageal Cancer—A Review
por: Han, Dan, et al.
Publicado: (2022) -
Survival after neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: A meta‐analysis
por: Fan, Mengying, et al.
Publicado: (2015) -
Neoadjuvant immunotherapy for resectable esophageal cancer: A review
por: Li, Qing, et al.
Publicado: (2022)